Champions Oncology, Inc. (FRA:2I3)

Germany flag Germany · Delayed Price · Currency is EUR
4.980
+0.200 (4.18%)
Last updated: Feb 20, 2026, 3:25 PM CET
Market Cap68.60M -51.6%
Revenue (ttm)50.65M +9.1%
Net Income2.16M
EPS0.15
Shares Outn/a
PE Ratio31.76
Forward PE116.12
Dividendn/a
Ex-Dividend Daten/a
Volume170
Average Volumen/a
Open5.100
Previous Close4.780
Day's Range4.980 - 5.100
52-Week Range4.780 - 10.200
Betan/a
RSI40.29
Earnings DateMar 13, 2026

About Champions Oncology

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1985
Employees 213
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 2I3
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements